IO Biotech Presents Pre-Clinical Data Highlighting the Potential of Additional Therapeutic Cancer Vaccine Candidates at the 2025 Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
(NASDAQ:IOBT), Pre-clinical data for IO Biotech's next T-win vaccine candidate, IO112 targeting arginase 1, demonstrates anti-tumor activity with dynamic changes in the tumor microenvironment (TME) driven by the vaccine-targeted modulation of immunosuppressive myeloid cells, including tumor-associated macrophages (TAMs) Pre-clinical data for IO Biotech's additional T-win vaccine candidate, IO170 targeting Transforming Growth Factor (TGF)-B, demonstrates induction […]